Richard Donovan Creative & Digital 2024

Valneva: Ixiaro vaccine.

Travel awareness digital and print campaign highlighting the dangers of Japenese encephalitis caused by mosquito bites in the Asia-Pacific Region.

No Filter: How well are your kidneys really working?

No Filter: How well are your kidneys really working? The

Look at your kidneys with No Filter to avoid having kidneys that offer No Filter in the future. DISCOVER THE TRUTH ABOUT YOUR KIDNEY HEALTH PATIENT INFORMATION BOOKLET

Help transform chronic kidney disease management across your market with our new ‘No Filter’ campaign!

No Filter: Discover the truth about your patient’s kidney health

Don’t take your kidney health for granted.

What is chronic kidney disease (CKD) and why is it important to know the facts?

It is estimated that 9 out of 10 people with CKD don’t know they have it.2 Know your risks and safeguard

AstraZeneca: No Filter: CKD awareness campaign.

Digital and print campaign to highlight awareness of chronic kidney disease.

Included printed patient booklets and editable social media assets.

AstraZeneca: forxiga times magazine homepage. Digital development for client who requested a move from standard infographic pdf shared on email to a newsletter style landing page to create more engagement. Landing page and supporting pages were designed and supplied in XD enabling the client to understand the user journey.

Alpharmaxim: Dementia Action Week social campaign 2023. Motion video and flat posts to raise awareness of the cognitive and physical effects of dementia on the lives of both individuals and their loved ones.

Features AI generated images via Midjourney.

EXAMPLE ON VIMEO

What is hyperkalaemia, and what causes it?

Understanding the condition and approaching potential solutions with No Filter can protect your kidneys now and in the future

High levels of potassium in the blood may be due to kidney problems or medications that affect the body’s ability to remove potassium from the blood1

Kidneys work as a filter to remove excess potassium, which may rise to dangerous levels if the kidneys are not working properly.1 Nearly 25% of patients with advanced stages of chronic kidney disease have hyperkalaemia2

Remember: staying on a prescribed dose of heart and blood pressure medication is key to maintaining a healthy heart and kidneys

A diet rich in fruits and vegetables is also recommended to help with heart and kidney health3,4

Modifying your diet, with a focus on low-potassium foods5

Using a long-term treatment for high levels of potassium6

Discuss

your

dialysis treatment5

Here are some of our 2023 highlights!

8 International markets contributed a significant of all clinical trial participants

If you have high potassium, create a daily routine to plan and manage the diet and/or medication prescribed to you by your healthcare provider To learn

40+ 12 26 experts engaged by network countries attending the 5th quarterly CoVEEN meeting with from experts

RSV Nurse Education Programme

Combines traditional online learning platforms with interactive gamification of education content for RSV.

1,300+ 25

registered users from countries

76% to 89%

increase in awareness of disease burden and methods of disease prevention by the end of the second month

AstraZeneca: Infographic creative and production. Departmental infographics created for sharing with internal AstaZeneca comms teams on social media and email.

Docquity HCP Education Project

Leveraging Docquity, Asia’s largest digital network, to provide targeted medical education and disease awareness materials beyond Asia.

INTERNATIONAL WOMEN’S DAY

For International Women’s Day, Alpharmaxim is highlighting the dynamic relationships between our male and female colleagues. This is how we #EmbraceEquity with Jess and Dan…

ESSENTIAL COOPERATION

What’s fantastic is that Favi and I try to collaborate as much as possible on projects. We bounce ideas off each other exceptionally well and really value each other’s input. Our differing design thinking and perspectives offer real variety in our approach, providing clients greater depth in project output.

Our backgrounds and experiences are diverse too, as we’ve trained and worked in different countries and environments. It’s an engaging mix that provides great scope for our work together, and strengthens the wider workplace. Creative

EMBRACING DIFFERENCES

From my first conversation with Ben, I could tell that he is a very empathetic person who values talent and creativity regardless of gender or background. I was initially a little uneasy, as in previous jobs I’d mainly worked in teams led by strong women.

Ben and I established a healthy working relationship by understanding and embracing our differences, and recognising our strengths (and weaknesses) based on mutual respect and team-centred goals. This undoubtedly gives us opportunities to thrive. We have built a solid alliance founded on trust and professionalism. Senior Creative

SHARED LEARNING

Adrian and I have a working partnership that allows us both to bring our strengths to the forefront. He has been instrumental in supporting me through my first years in MedComms. He’s been a guide, sharing knowledge and helping me navigate solutions calmly and professionally, but he’s also welcomed my ideas and the different perspective and approaches I have been able to bring.

I enjoy working with Adrian as he’s great at utilising his expertise to challenge a client’s thinking, to ensure their proposed plans align with their overarching story. We work together effectively because we both want the best for our clients and the rest of our internal team.

Account Manager Robyn

Alpharmaxim: International Women’s Day campaign 2023.

Flat carousel posts including photography featuring the Alpharmaxim internal team.

Lupin: NaMuscla Mexiletine Detail Aid. Creative front cover concepts for HCP detail Aids.

Lupin: NaMuscla Mexiletine Dosage card.

A4 print and interactive digital PDF.

Patients with renal or hepatic impairment1

Dose adjustment is not required for patients with mild or moderate renal impairment. Use in patients with severe renal impairment is not recommended

Caution should be used in patients with mild or moderate hepatic impairment. In these patients, it is recommended that the dose should only be increased after at least 2 weeks of treatment. Use in patients with severe hepatic impairment is not recommended

Effects on ability to drive and use machines1

Mexiletine may have a minor influence on the ability to drive and use machines. Fatigue, confusion and blurred vision may occur following administration of mexiletine

Intake of caffeine1

Clearance of caffeine is decreased following the administration of mexiletine. Caffeine intake should be reduced during treatment with mexiletine

Smoking1

Total clearance of mexiletine is significantly increased in smokers due to induction of CYP1A2. Mexiletine dose may need to be increased if a patient starts to smoke during treatment and decreased if they stop smoking

Precautions

Clinical Frontiers in CF

The gold standard of diagnostic techniques

Microbiological culture is the current gold standard in lung infection diagnosis.2,3 A longitudinal, observational study in the United Kingdom compared microbiological culture with targeted quantitative PCR (qPCR) for the detection of Pa and Staphylococcus aureus infections in patients with CF.3 Ninety patients believed to be Pa-negative were enrolled, of which 40 were included in the longitudinal analysis (20 pediatric [mean age: 10.5 years] and 20 adult [mean age: 25.1 years]).3 Respiratory samples were collected via sputum or cough swabs. Mean Pa detection was significantly lower by culture compared with qPCR in pediatric and adult patients (p<0.0001).3 Mean S. aureus detection was also significantly lower by culture compared with qPCR in both pediatric and adult populations (p<0.0001 and p=0.034, respectively).3

In the age of CF transmembrane conductance regulator (CFTR) modulator therapy, this underestimation of infection prevalence by culture may be augmented due to reliance on culture of specimens less sensitive than sputa, such as cough swabs, as a result of CFTR modulator therapy reducing sputum production.3

In this edition, we present findings from a number of recent trials that highlight the current challenges and advances in the diagnosis of lung infections in patients with cystic fibrosis (CF).

AtbFinder, a novel, culture-based diagnostic test system, can help select effective antibiotics by evaluating their efficacy against biofilms, using biological samples.1 A prospective, non-randomized, open-label clinical trial investigated the efficacy of antibiotics selected using AtbFinder in 35 patients with CF recruited from Saint Petersburg Medical University, Russia (age range: 15–59 years).

Diagnostic obstacles in the age of CFTR modulator therapy

The number of pulmonary exacerbations and hospitalizations due to exacerbations 1 and 2 years post-initiation with antibiotics selected by AtbFinder was significantly reduced compared with years –1 and –2 (using routine antibiotic selection methods; p<0.001) and Pseudomonas aeruginosa (Pa) was cleared from 81.8% of patients within 2 years.1 These results suggest that AtbFinder is able to facilitate the selection of effective antibiotics, ensuring better clinical outcomes compared with conventional selection methods.1

BRIO was a prospective, observational study conducted in France over 24 months in patients with CF (129 patients enrolled, mean age at initiation: 19.1 years).4 It demonstrated a reduction in positive cultures for respiratory pathogens post-CFTR modulator therapy; however, infection persisted in the majority of patients (90.9% pre-ivacaftor vs 75.8–83.3% post-ivacaftor),4 emphasizing the importance of continued infection monitoring.

“AtbFinder, with as little as 4-h turnaround time, can improve net health outcomes by the selection of more effective antibiotics compared to conventional therapeutic approaches.” 1

Another prospective, observational study in Germany aimed to assess the effect of high efficiency modulator therapy (HEMT) with elexacaftor–tezacaftor–ivacaftor on the airway microbial metagenome of 31 enrolled patients (age: ≥12 years) with pancreatic-insufficient CF.5 Airway metagenomes were constructed from sputum and/or deep cough swabs pre-HEMT (Visit 1) and at 14±5 weeks (Visit 2) and 50±14 weeks (Visit 3) post-HEMT initiation. Median DNA load decreased from Visit 1 to Visit 3 for Pa (32 to 0), S. aureus (2.2 to 0), and Haemophilus influenzae (0.43 to 0.003). The authors concluded that HEMT successfully lowers Pa S. aureus, and H. influenzae load.5

The gold standard of diagnostic techniques

However, the study also demonstrated an increased failure rate of sputum induction with increased time on CFTR modulator therapy (Figure 1); a potential obstacle for infection monitoring in patients on this therapy.5

Microbiological culture is the current gold standard in lung infection diagnosis.2,3 A longitudinal, observational study in the United Kingdom compared microbiological culture with targeted quantitative PCR (qPCR) for the detection of Pa and Staphylococcus aureus infections in patients with CF.3 Ninety patients believed to be Pa-negative were enrolled, of which 40 were included in the longitudinal analysis (20 pediatric [mean age: 10.5 years] and 20 adult [mean age: 25.1 years]).3 Respiratory samples were collected via sputum or cough swabs. Mean Pa detection was significantly lower by culture compared with qPCR in pediatric and adult patients (p<0.0001).3 Mean S. aureus detection was also significantly lower by culture compared with qPCR in both pediatric and adult populations (p<0.0001 and p=0.034, respectively).3

“The diagnostic gold standard of microbiological detection by culture may significantly underestimate prevalence.”3

A prospective, multi-center, longitudinal cohort study aimed to use paired sputum and cough swabs from patients with CF from Amsterdam University Medical Centers, Netherlands (55 patients recruited; 25 pediatric and 30 adult) to determine the validity of cough swabs for pathogen detection.6 The median overall bacterial richness was significantly higher in adult and pediatric patients from sputum samples compared with cough swabs (p<0.001 and p=0.036, respectively).6 The authors concluded that culture-independent analysis of cough swabs, particularly in adult patients with CF, may provide inaccurate results.6

Diagnostic obstacles in the age of CFTR modulator therapy

Alternative techniques may provide diagnostic solutions

BRIO was a prospective, observational study conducted in France over 24 months in patients with CF (129 patients enrolled, mean age at initiation: 19.1 years).4 It demonstrated a reduction in positive cultures for respiratory pathogens post-CFTR modulator therapy; however, infection persisted in the majority of patients (90.9% pre-ivacaftor vs 75.8–83.3% post-ivacaftor),4 emphasizing the importance of continued infection monitoring.

Recent studies investigated the feasibility of breath analysis for diagnosis of lung infection in patients with CF.7,8 A cross-sectional study identified volatile organic compounds (VOCs) associated with Pa from the literature and used targeted exhaled breath analysis to identify Pa-positive individuals.7 Patients were recruited from the Amsterdam University Medical Centers, Netherlands (N=53; 25 pediatric, 28 adult). The authors concluded that decreased ethyl acetate concentration in exhaled breath could provide good Pa diagnostic accuracy in pediatric patients, while similar diagnostic accuracy could be achieved by measuring a composite model of five VOCs in adults.7

A cross-sectional proof-of-concept study was conducted in pediatric patients with either CF (N=99) or asthma (N=32) in the Netherlands. Exhaled breath samples were collected using a modular breath sampler (MBS), and cough swabs or sputa samples. Differences in bacterial type identified using the MBS compared with swabs or sputa were observed and, notably, Pa was detected more often with the MBS.8

However, the study also demonstrated an increased failure rate of sputum induction with increased time on CFTR modulator therapy (Figure 1); a potential obstacle for infection monitoring in patients on this therapy.5

Pseudomonas aeruginosa was detected more often in MBS than in swab or sputum samples.” 42 9% 96 4%

In the age of CF transmembrane conductance regulator (CFTR) modulator therapy, this underestimation of infection prevalence by culture may be augmented due to reliance on culture of specimens less sensitive than sputa, such as cough swabs, as a result of CFTR modulator therapy reducing sputum production.3 42

Another prospective, observational study in Germany aimed to assess the effect of high efficiency modulator therapy (HEMT) with elexacaftor–tezacaftor–ivacaftor on the airway microbial metagenome of 31 enrolled patients (age: ≥12 years) with pancreatic-insufficient CF.5 Airway metagenomes were constructed from sputum and/or deep cough swabs pre-HEMT (Visit 1) and at 14±5 weeks (Visit 2) and 50±14 weeks (Visit 3) post-HEMT initiation. Median DNA load decreased from Visit 1 to Visit 3 for Pa (32 to 0), S. aureus (2.2 to 0), and Haemophilus influenzae (0.43 to 0.003). The authors concluded that HEMT successfully lowers Pa S. aureus, and H. influenzae load.5

Viatris and AstraZeneca email creative.

A novel pathogen detection system based on acquiring the scattered light signals from incubated microdroplets is also in development. In test samples clinically prepared using Pa, a study reported that this technique detected Pa with a maximum classification accuracy of 95.6% using sample concentrations of 105 CFU/mL.9 The results suggest this novel system could potentially aid lung infection diagnosis in the future.

Finally, a study investigated the suitability of a thermal sensor for the indirect detection of Pa infection using molecularly imprinted polymers that detect pyocyanin (a toxin secreted by Pa).10 It demonstrated that the technology is selective for pyocyanin in solutions with concentrations mimicking the lowest pyocyanin concentration found in saliva, sputum, or urine samples.10 Further studies are required to understand the performance of the sensor in clinical samples 10

Monthly newsletter and webinar interactive designs. Upon client approval, designs are cut and supplied for mail merge.

A prospective, multi-center, longitudinal cohort study aimed to use paired sputum and cough swabs from patients with CF from Amsterdam University Medical Centers, Netherlands (55 patients recruited; 25 pediatric and 30 adult) to determine the validity of cough swabs for pathogen detection.

6 The median overall bacterial richness was significantly higher in adult and pediatric patients from sputum samples compared with cough swabs (p<0.001 and p=0.036, respectively).6

The authors concluded that culture-independent analysis of cough swabs, particularly in adult patients

AstraZeneca: World Kidney Day animated gif. A series of 10 educational animated gifs for AstraZeneca’s workplace social media platform. Designed as a mutiple choice game to create awareness and engagement.

Please click on the link to see an example.

AstraZeneca: A Catalyst Manifesto (Internal Social Media)

Internal Promotional video.

AstraZeneca: CVRM Highlights Video. (Internal Social Media) CVRM Townhall 2024.

Alpharmaxim: World Alzheimer’s Day campaign. (Social Media)

This video won a Viddy Awards gold 2023.

Alpharmaxim: International Med Comms Day. (Social Media)

Feel good video explaining the process of a creative project in a Med Comms Agency.

Motion and video projects.

A small selection of motion and video projects I have worked on for both AstraZeneca and Alpharmaxim.

First blue Healthcare. Recruitment creative.

Flat carousel posts.

First blue Healthcare. Your VR Therapy Landing page.

Initial branding and digital creative for supply to development team in XD.